← Back to DonatienInvestment Report archive →

NYSE:MRK Merck & Co., Inc.

ISIN: US58933Y1055
Health CarePharmaceuticalsLarge-Cap DefensiveKeytruda 2028 patent cliff
NYSE · Rahway, NJ · Drug Manufacturers — General · Mkt cap ~$324B Analysis Status: On-Going
$131.07
+0.45%
25 Jul 2026 · Signal v6
What changed vs 10 Jul 2026 (last update):
DISCLAIMER: This is a quantitative framework for educational purposes only. It is not financial advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Merck & Co., Inc.

Merck & Co. (NYSE:MRK) is one of the world's largest pharmaceutical companies, built around human-health medicines and vaccines plus a sizeable Animal Health division. Its economic engine is Keytruda, the leading PD-1 cancer immunotherapy, which anchors a broad oncology franchise alongside vaccines (Gardasil, pneumococcal), the fast-growing pulmonary-hypertension drug Winrevair, and hospital/specialty products. Its edge is scale in R&D and a deeply embedded position as standard-of-care in many cancer regimens, protected by patents and manufacturing know-how. The defining investor question is concentration: Keytruda is roughly 40-45% of pharma sales and loses US patent exclusivity in 2028, so the whole thesis turns on whether the pipeline and a subcutaneous Keytruda (Qlex) can backfill that cliff. Think of Merck as a cash-generative, high-margin drug maker racing to diversify before its biggest product goes off-patent.

HorizonSignalComposite ScoreConfidenceKey Driver
Short-term (1–3 mo)HOLD4540%Buy on confirmation — at 52-wk high, entry edge gone
Medium-term (6–12 mo)BUY6364%Cheap quality compounder + Health Care tailwind
Long-term (3–5 yr)BUY6568%Durable franchise, pipeline backfilling the 2028 cliff
Next update: 2026-08-05 — Q2 2026 earnings 2026-08-04 (BMO) +1 trading day — the binary event; beats the default +14d (2026-08-08)
Table of Contents
1Five-Pillar Scorecard2Hard Gates & Do-Not-Buy Status3Pillar Detail: Business Quality4Pillar Detail: Valuation Attractiveness5Pillar Detail: Underlying Drivers6Pillar Detail: Economic Alignment7Pillar Detail: Entry/Exit Timing8Economic Event Risk9Multi-Timeframe Technical Analysis10Price Chart (6-Month Daily)11Scenario Summary12Entry / Exit Rules13Position Sizing Context14Calibration Snapshot15Data Sources & Methodology
1

Five-Pillar Scorecard

Five independent scores — each 0–100 with its own confidence. The three fundamental pillars (Quality / Valuation / Timing) set the base BUY/HOLD/SELL via the Decision Matrix; the two context pillars (Underlying Drivers, Economic Alignment) then amplify a BUY to STRONG BUY or a SELL to STRONG SELL when both corroborate.

Business Quality

68
good — durable, concentrated
conf 70%

Valuation Attractiveness

66
attractive/fair boundary
conf 68%

Entry/Exit Timing

57
strong trend, poor R:R at highs
conf 40%

Underlying Drivers

55
Neutral
conf 60%

Economic Alignment

65
Trend-Following
conf 66%
2

Hard Gates & Do-Not-Buy Status

Binary safety checks — any TRIGGERED gate is a hard cap regardless of the scores above; CAUTION gates are sizing notes.
✅
Financial Distress
Net debt ~$43B, Net Debt/EBITDA ~2.0x, interest coverage 17.4x, current ratio 1.30. No distress.
⚠️
Earnings Event Risk
⚠️ Q2 2026 earnings 2026-08-04 (BMO) — within 14 days. MRK can move >5% on prints; Timing confidence capped at 40%. Binary for the Short.
✅
Valuation Ceiling
Clean fwd P/E 14.6x is far below the Health Care rich line (22x) and the $155 high target; anchor ratio 0.82 (< 1.40). Not expensive.
⚠️
Accounting / Earnings Quality
⚠️ Q1-26 GAAP EPS −$1.72 is distorted by a ~$9B one-off acquired-IPR&D charge (Cidara/Verona/Terns). Scored on CLEAN ~$9.0 forward EPS, not reported. Disclosed & non-recurring — caution, not a trigger.
⚠️
Regulatory / Binary Event
⚠️ IRA drug-price negotiation and the 2028 Keytruda LOE are structural, well-known headwinds — scored (driver/quality), not a make-or-break binary. No single pending FDA decision gates the name.
Hard-gate state: CAUTION (clear, with flags). No gate blocks the signal and no Do-Not-Buy trigger fires. Two live cautions shape the Short: an earnings print inside 14 days (event risk) and the GAAP/clean-earnings gap (scored clean). The Keytruda cliff + IRA are carried as scored headwinds, not gates.
3

Pillar Detail: Business Quality

A deep dive into the Quality score: business economics, moat, ROIC and the industry benchmark.
Business Quality — Pillar Score
Good — a high-margin, high-return franchise with a single-product concentration overhang
68
conf 70%

Lifecycle: Mature pharma. Merck is a cash-cow drug maker with a genuine quality core — but one whose durability is hostage to Keytruda's 2028 US loss-of-exclusivity. The margins and returns are top-tier; the concentration is the caveat that keeps this a 68, not an 80.

Sub-signalValueRead
Operating margin (TTM)38.6%Excellent — pricing power intact
Gross margin76%Strong
ROE / ROA18.9% / 12.6%High returns on capital
Interest coverage17.4xBalance sheet safe
Revenue growth (TTM)~+5%Modest; Gardasil China a drag
Share count2.54B → 2.47BShrinking — buybacks, no dilution
INDUSTRY BENCHMARK: R&D Efficiency + Patent Cliff — 55/100. Keytruda is ~40-45% of pharma revenue and loses US exclusivity in 2028 — patent-cliff exposure is well above the >30% “red flag” line, and revenue durability fails the >50%-from-a-single-drug test. Offsetting it: a deep, de-risking pipeline — Winrevair (PAH, $525M in Q1-26, +88% YoY, $5-7B peak potential), subcutaneous Keytruda Qlex ($128M in Q1, targeting 30-40% conversion by 2028 to blunt the biosimilar hit), plus Welireg, Enflonsia and cardiometabolic assets. Mixed — hence a middling benchmark score.
Pricing power72
Network effects50
Switching costs60
Cost advantage62
Intangibles (patents/brand)72
Moat average63

The moat is real but decaying on a clock: Keytruda's patent + standard-of-care embedding score high today, but the switching-cost and intangible walls fall away as 2028 biosimilars arrive. That is why the moat sub-score sits at 63, not 80.

Competitive Environment (MANDATORY). Merck competes across oncology-immunology with Bristol Myers Squibb (Opdivo, itself facing LOE), AstraZeneca (Imfinzi + a broad oncology book), Pfizer, Merck KGaA and Roche. The sharpest emerging threat is the PD-1/VEGF bispecific class — Summit Therapeutics' ivonescimab (partnered with Akeso) — which in some trials has challenged Keytruda monotherapy and could pressure share even before 2028. At LOE, at least seven disclosed pembrolizumab biosimilar programs (Samsung Bioepis, Amgen, Sandoz, Celltrion, Bio-Thera and others) queue to erode US Keytruda. Share trajectory: stable today, structurally at risk from 2028. This decaying-lock-in read is the direct input to the Switching-Costs (60) and Cost-Advantage (62) sub-scores above, and it seeds the §11 Bear trigger and the §12 thesis-invalidation.
RivalBattlegroundTrajectory vs MRK
Bristol Myers (BMY)IO / OpdivoPeer, own LOE pressures
AstraZeneca (AZN)Oncology breadthGaining in solid tumours
Summit / Akeso (ivonescimab)PD-1/VEGF bispecificEmerging Keytruda threat
Pembro biosimilars (7+ filers)Post-2028 US KeytrudaExistential to the cash cow
ROIC & Capital Allocation — 70/100. High, durable ROIC; disciplined buybacks (share count falling); dividend well-covered on clean earnings ($3.40 vs ~$9.0 clean EPS = ~38% payout, despite a scary 92% payout on distorted GAAP). Recent bolt-on M&A (Cidara, Verona, Terns) is the source of the Q1 IPR&D charge — aimed squarely at diversifying past Keytruda.
4

Pillar Detail: Valuation Attractiveness

Sector-appropriate multiples, FCF yield, reverse-DCF implied growth, embedded optionality, and the analyst-consensus cross-check.
Valuation Attractiveness — Pillar Score
Attractive/fair boundary — genuinely cheap on clean earnings, but less so after a 5% run + higher 10Y
66
conf 68%

Warranted-Multiple Anchor. r = 4.69% (10-Y UST, 2026-07-24) + 4.5% ERP + 0.0% (Quality ≥ 65) = 9.19%. Disciplined growth: g_near 4.5% (0.75 × ~6% consensus, Health-Care cyclical cap 10%), g_term 3.0%. Two-stage warranted P/E ≈ 17.7x (below the 22x Health-Care guardrail, so uncapped).

MetricValueRead
Actual clean fwd P/E14.6xon ~$9.0 clean EPS
Warranted P/E17.7xrate + disciplined growth
Anchor ratio (actual ÷ warranted)0.82Attractive/fair edge
Reported TTM P/E36.9xDistorted by Q1 IPR&D charge — ignore
FCF yield (clean / reported)~5.5% / 4.4%Solid cash generation
Dividend yield2.6%~38% payout on clean EPS
Own-history decile3rdCheap vs its own 5-yr range
PEG (fwd)~2.4Low growth caps PEG appeal
Band: Attractive/fair boundary (ratio 0.82, score 66). Down from 0.77 / score 68 last update — driven by BOTH the ~5% price rise to a 52-wk high AND the 10-Y climbing 4.56% → 4.69% (oil-shock yields), which compressed the warranted multiple 18.1x → 17.7x. Still cheap in absolute terms: 14.6x clean forward earnings for a 38%-margin, 19%-ROE franchise is well under the 22x sector rich line and below the pharma peer median (~15-16x). The relative lenses (sector median, decile-3 own history, Buy grades consensus) all sit attractive; PEG is the one soft spot (low growth). Analyst consensus: target $136.33 (+4%), median $142 (+8%), high $155, low $100; 25 Buy / 11 Hold / 1 Sell; FMP rating B (3/5). The +4% to consensus is what makes this a value hold at the high, not a chase.
5

Pillar Detail: Underlying Drivers

The dominant external force the stock is tethered to, scored 0–100. A context pillar: it does not change the base signal — it feeds amplification (tailwind ≥65 can lift BUY→STRONG BUY; headwind ≤35 can push SELL→STRONG SELL).
Primary Driver
Pipeline build-out vs. Keytruda patent cliff (2028 LOE + IRA drug pricing)
55
Neutral — no amplification

Merck's fortunes hinge on one tug-of-war: can the pipeline out-run Keytruda's 2028 cliff? Right now the forces roughly balance, so the driver is Neutral (55) and does not amplify the base signal.

HorizonNet driverWhy
ShortNeutralQ2 print + Winrevair ramp vs Gardasil-China drag
MediumNeutralQlex conversion + pipeline readouts vs IRA/ivonescimab noise
LongNeutral-to-headwind2028 biosimilar erosion is the defining unknown

Tailwinds: Winrevair (+88% YoY, $5-7B peak); Qlex subcutaneous Keytruda de-risking the cliff via IV→SC conversion; a broad late-stage pipeline management says can deliver ~$70B of new-product revenue by the mid-2030s. Headwinds: the 2028 Keytruda LOE; Gardasil weakness in China (−39% in 2025, no 2026 rebound); IRA price negotiation; and the ivonescimab / PD-1-VEGF competitive class. Amplification: none — at 55 the driver is in the 36-64 no-amp band, so the base BUY stays BUY (it does not become STRONG BUY), and valuation (ratio 0.82 < 1.20) would have permitted it were the driver stronger.

6

Pillar Detail: Economic Alignment

How the current economic climate sits relative to this stock, read from the latest Macro-Economic report. Classifies the macro pressure (Tailwind / Neutral / Headwind) — the second amplification input — and frames a long entry as Trend-Following or Contrarian with a 0–100 conviction.
Stance · Pressure
Trend-Following · Tailwind
65
conviction

The 2026-07-20 macro report reads the regime as stagflation-lite (energy-supply-shock driven). Health Care (XLV) is scored Outperform across ALL three horizons (short O / medium O / long O) with real+fast money flowing IN — a defensive, earnings-durable winner in a slowing, sticky-inflation tape. As a low-beta (0.20) mega-cap pharma, MRK is squarely in the sector the macro favours: a genuine Tailwind. The ARMED AI-concentration tail does NOT apply — MRK is not an AI-cohort name and carries no inherited de-rating bear leg.

Source: sector-map · Macro report 2026-07-20

7

Pillar Detail: Entry/Exit Timing

The risk-reward framework, relative strength vs SPY and the sector ETF, the macro overlay, news-derived sentiment, and the catalyst cluster.
Entry/Exit Timing — Pillar Score
Strong uptrend across every timeframe — but at the 52-wk high with a compressed reward-to-risk
57
conf 40% (earnings-event capped)

Multi-timeframe: strongly bullish confluence. Monthly, weekly and daily are all in uptrend / strong uptrend with resistance breakouts; price ($131.07) sits right on the 52-wk high ($131.74), above the rising 20/50/200-day averages. RSI is a non-extreme 62 (daily) / 66 (monthly) — room, not exhaustion. The only soft note: today's breakout is on 0.65× average volume (unconfirmed), and the 15-min is weakening intraday.

InputReadingRead
Trend (M/W/D)Up / Up / Strong upConfluence strongly bullish
RSI (daily)62Healthy, not overbought
Relative strength+71% off 52-wk lowSector leader YTD
Reward-to-risk+4% to consensus vs −16% bearPoor at the high
Breakout volume0.65× avgUnconfirmed
Short-horizon technical-confirmation cap FIRES. The base Short signal is BUY, but it rests on the Fundamental group alone (cheap). The Technical entry group is UNMET — the breakout lacks >1.5× volume and price is at the high, not at support — and there is no live Catalyst. Per the DECK-2026 rule, a Short BUY with no confirmed timing path is capped to HOLD — “Buy on confirmation”: a pullback into ~$126 (EMA20) / $121 (50-day) support, or a volume-backed push through $131.74. Medium and Long are unaffected — quality + value carry them to BUY. Timing confidence is additionally capped at 40% by the earnings-event gate (Aug 4).
8

Economic Event Risk

High-impact macro releases in the next 14 days that could swing this stock, plus the last 7 days of surprises.

Upcoming events (next 30 days)

DateEventImpactForecastPreviousRelevant?Why
2026-07-29FOMC decision (Warsh)HighHold / hawkish—Low (indirect)Rate path sets the 10-Y in the valuation anchor; pharma is low-rate-sensitivity
2026-08-04MRK Q2 2026 earnings (BMO)HighNon-GAAP EPS ~$1.36—HIGHBinary for the Short — Keytruda/Winrevair trajectory, Gardasil China, FY guide
2026-07-31Core PCEMed——LowConfirms the inflation leg of the regime

Recent surprises (last 7 days)

DateEventActualForecastSurpriseImpact
2026-07-13Analyst maintains (Guggenheim/JPM/BMO)Buy/OW/OP—In-lineNeutral-positive
2026-04-30Q1 2026 earningsGAAP −$1.72 (IPR&D charge)—Non-GAAP beat, cleanNeutral

The Aug-4 Q2 print is the dominant near-term event and the reason the next update is scheduled for Aug 5. FOMC/PCE matter only indirectly (via the 10-Y in the valuation anchor); pharma is a low-macro-sensitivity sector.

9

Multi-Timeframe Technical Analysis

Trend, RSI and breakout status across monthly / weekly / daily / hourly / 15-minute, with a confluence verdict.
TimeframeTrendDirectionRSIMACDKey S/RBreakoutVol
MonthlyUptrend↑66+Res $134.6 / Sup $99Resistance breakout0.55x
WeeklyUptrend↑63+Res $125 / Sup $106Resistance breakout0.78x
DailyStrong uptrend↑62+Res $131.7 / Sup $111Resistance breakout0.65x
HourlyStrong uptrend↑53−Res $131.7 / Sup $126At resistance—
15-minWeakening↓40−Res $131.7 / Sup $130Support breakdown—
Confluence: Strongly bullish (higher timeframes); short-term stalling at the 52-wk high · MTF Score 72

Every higher timeframe is bullish and price just broke to a fresh 52-wk high — a leader, not a laggard. But the breakout is on light volume and the intraday frames are stalling right at resistance, which is exactly why a fresh 1-3 month long is better taken on a pullback or a volume-confirmed breakout than at the high itself.

10

Price Chart (6-Month Daily)

A 6-month daily close line with SMA50 and key support/resistance — the visual companion to the MTF table.

MRK at the 52-wk high, extended above a rising 50-day. Preferred long entry: pullback into $126/$121 support, or a volume-backed break of $131.74.

11

Scenario Summary

Bull / Base / Bear 12-month price paths with triggers and probability weights.

Bull $150 (25%)

Q2 beats and the FY guide is raised; Winrevair accelerates toward its $5-7B peak; Qlex subcutaneous conversion visibly de-risks the 2028 cliff; positive pipeline readouts. The market re-rates a diversifying franchise toward ~16-17x on ~$9+ clean EPS → ~$150 (near the $155 high target).

Base $142 (50%)

Steady execution: Q2 roughly in-line, Keytruda holds while Qlex + Winrevair offset Gardasil-China softness, clean EPS ~$9.0-9.6. The 2028 cliff stays a known, partially-hedged risk. Modest re-rate to the consensus median → ~$142 (12-mo). Most probable.

Bear $108 (25%)

Competitive/erosion trigger: ivonescimab data or biosimilar-cliff fears pull Keytruda share expectations forward; Gardasil China deteriorates further; a Q2 miss or soft guide and a harsher IRA outcome. The multiple compresses toward ~12x → ~$108-110. The named-rival (ivonescimab / 7 pembro biosimilar filers) share-loss path is the explicit downside.

Probability-weighted fair value ≈ $135 (0.25×150 + 0.50×142 + 0.25×108). Essentially the current price — the market is paying fair-to-slightly-cheap for a franchise whose 2028 risk is real but well-flagged. The asymmetry favours patient accumulation on weakness, not a chase at the high.

12

Entry / Exit Rules

Three independent entry paths (Fundamental · Technical · Catalyst) and three exit triggers (Stop-Loss · Thesis · Profit-Target). Any one entry path is a valid entry — the more that agree, the larger the position the conviction ladder suggests. Exits are graded by severity, not count.

How to read this — the Conviction Ladder

The three entry groups are alternative paths to a buy, not a checklist. A group counts only when all its sub-conditions hold. How many groups are satisfied sets the suggested size — it does not gate whether you may enter: 1 group = Half-Size (a valid starter/scale-in), 2 = Full-Size, 3 = Over-Size (highest conviction); 0 = Wait (no path open yet). A strong overall signal can still read Wait here when the stock is well above its entry zones — that flags "good business, no entry edge right now," not a contradiction. Exits are graded by severity of what is live, not by a count: a hard stop is an Exit on its own.
Entry conviction: Half-Size1 of 3 groups met — one path open — starter / scale-in

Fundamental — MET

Cheap on clean earnings, driver not a headwind, no earnings inside 7 days.
✅ Price $131.07 < fair value ~$142
✅ No earnings within 7 days (Q2 is 10 days out, Aug 4)
✅ Underlying-Driver score ≥ 50 (55)

Technical — not MET

In a strong uptrend but the breakout is unconfirmed (light volume) and price is at the high, not at support — no reachable technical entry today.
⛔ Daily close > 50-DMA ($121) on > 1.5× volume (today 0.65×)
⛔ OR a tested bounce off $121/$126 support with a higher low
✅ RSI 35-65 (62)
✅ MACD histogram positive (daily +0.26)

Catalyst — not MET

No confirming event yet — Q2 earnings (Aug 4) is the next catalyst.
· Post-earnings move > +5% with guidance raised
· Volume > 2× average on the move

Forecast: One group met (Fundamental) → Half-Size. The Technical group opens on a pullback into $126/$121 with a higher low, OR a volume-confirmed (>1.5×) daily close above $131.74 — either would confirm the Short and lift size toward Full. The Catalyst group could open on an Aug-4 beat-and-raise (>+5% on >2× volume).

Exit action: Holdno exit trigger is live — hold the position

Stop-Loss — not LIVE

⛔ Two daily closes below $118 (below the 50-day and recent structure)

Thesis Invalidation — not LIVE

⛔ FY guidance cut, OR Keytruda/Winrevair trajectory disappoints
⛔ Ivonescimab / biosimilar erosion set to outpace the pipeline backfill (driver flips to Headwind)
⛔ A harsher-than-expected IRA outcome

Profit-Target — not LIVE

⛔ Price into the $142 median target AND RSI > 70 AND quality unchanged

Forecast: No exit trigger live — Hold. Price is ~11% above the $118 stop; the thesis is intact. Trim only into $142+ on an overbought RSI.

Imagine you act at the current price of $131.07 · as of 25 Jul 2026

What if you bought now?

You are risking ~16% (to the $108 bear) to gain ~8% (to the $142 base) if you buy the full position at today's 52-wk high.

That reward-to-risk is why the Short is HOLD, not BUY. For a 6-18 month holder the math improves (durable franchise, cheap clean multiple, Health-Care tailwind), but the disciplined move is a starter Half-Size now and add on a pullback into $126/$121 — not a chase.

What if you sold now?

You are giving up a cheap, cash-generative compounder with a sector tailwind to avoid a known-but-flagged 2028 risk.

Selling here locks in the run but forfeits the Medium/Long BUY thesis. Better to hold the core and let the stop ($118) and the thesis-invalidation rules (guide cut / cliff erosion) do the de-risking.

13

Position Sizing Context

Illustrative portfolio math (not advice) translating conviction into an allocation given risk-per-share and volatility.
The §12 Conviction Ladder reads Half-Size (1 of 3 entry paths met — Fundamental only). No risk budget was provided, so no portfolio % is computed. For a Medium/Long holder this is a starter position to add to on a pullback; for a Short trader it is Wait for confirmation. Not a recommendation — size to your own risk tolerance and existing Health-Care exposure.
14

Calibration Snapshot

Machine-readable snapshot of every score, level and signal, saved alongside the HTML so the next run can compute deltas.
{
  "ticker": "MRK",
  "exchange_ticker": "NYSE:MRK",
  "isin": "US58933Y1055",
  "country_table": "US",
  "date": "2026-07-25",
  "version": "v6",
  "prior_report": "MRK_Signal_v6_20260710_0626.html",
  "analysis_status": "on-going",
  "finder_ticker": "MRK",
  "finder_exchange": "\ud83c\uddfa\ud83c\uddf8 NYSE",
  "section": "Defensive Health Care",
  "user_context": {
    "horizon": "all",
    "allocation_pct": null,
    "portfolio_role": null
  },
  "sector": "Healthcare / Pharma (Mature)",
  "lifecycle_stage": "mature",
  "currency": "USD",
  "company": "Merck & Co., Inc.",
  "price_at_rating": 131.07,
  "signal_short": "HOLD",
  "signal_medium": "BUY",
  "signal_long": "BUY",
  "primary_signal": "BUY",
  "short_entry_confirmed": false,
  "short_cap_reason": "Fundamental-only entry at the 52-wk high; Technical group unmet (breakout on 0.65x volume, not at support) and no live catalyst \u2014 capped to Buy-on-confirmation (pullback into $126/$121, or a volume-backed break of $131.74).",
  "quality_score": 68,
  "valuation_score": 66,
  "timing_score": 57,
  "driver_score": 55,
  "driver_label": "Neutral",
  "driver_name": "Pipeline build-out vs. Keytruda patent cliff (2028 LOE + IRA)",
  "economic_alignment_stance": "Trend-Following",
  "economic_alignment_conviction": 65,
  "economic_alignment_pressure": "Tailwind",
  "economic_alignment_source": "sector-map",
  "macro_report_date": "2026-07-20",
  "amplification_fired": false,
  "quality_detail": {
    "industry_benchmark_name": "R&D Efficiency + Patent Cliff",
    "industry_benchmark_value": "Keytruda ~40-45% of pharma revenue, US LOE 2028",
    "industry_benchmark_score": 55,
    "moat_score": 63,
    "roic_capital_score": 70,
    "keytruda_q1_2026_sales_usd_b": 8.0,
    "keytruda_qlex_q1_2026_sales_usd_m": 128,
    "winrevair_q1_2026_sales_usd_m": 525,
    "gardasil_2025_china_growth_pct": -39
  },
  "valuation_detail": {
    "clean_fwd_pe": 14.6,
    "reported_ttm_pe": 36.9,
    "clean_eps_runrate": 9.0,
    "analyst_fwd_eps": 9.65,
    "fcf_yield_reported": 4.4,
    "fcf_yield_clean": 5.5,
    "dividend_yield": 2.6,
    "payout_on_clean_eps_pct": 38,
    "consensus_growth_rate": 6.0,
    "historical_valuation_decile": 3,
    "iprd_charge_usd_b": 9
  },
  "warranted_multiple": 17.7,
  "actual_multiple": 14.6,
  "val_multiple_basis": "clean forward P/E",
  "discount_rate_r": 9.19,
  "risk_free_10y": 4.69,
  "g_near": 4.5,
  "g_term": 3.0,
  "warranted_ratio": 0.82,
  "val_band": "attractive",
  "nonop_pct_of_net_income": 100,
  "clean_pe": 14.6,
  "clean_peg": 2.4,
  "competitive_share_trajectory": "stable-now-at-risk-2028",
  "competitive_threat_level": "elevated",
  "competitive_rivals": [
    "Bristol Myers (BMY)",
    "AstraZeneca (AZN)",
    "Pfizer (PFE)",
    "Summit/Akeso ivonescimab",
    "pembrolizumab biosimilars (7+ filers)"
  ],
  "timing_detail": {
    "mtf_confluence": 72,
    "risk_reward_score": 46,
    "relative_strength": "very strong (+71% off 52wk low, at 52wk high)",
    "catalyst_clustering_score": 65,
    "breakout_volume_ratio": 0.65,
    "dynamic_macro_weight": 0.1
  },
  "analyst_consensus_target": 136.33,
  "analyst_target_high": 155,
  "analyst_target_low": 100,
  "analyst_target_median": 142,
  "analyst_target_upside_pct": 4.0,
  "analyst_grades_consensus": "Buy",
  "analyst_bullish_pct": 67.6,
  "analyst_coverage_count": 37,
  "recent_upgrades_30d": 0,
  "recent_downgrades_30d": 0,
  "fmp_rating": "B",
  "fmp_overall_score": 3,
  "overall_confidence": 40,
  "confidence_short": 40,
  "confidence_medium": 64,
  "confidence_long": 68,
  "fair_value_est": 142,
  "stop_loss": 118,
  "target_price": 142,
  "scenario_bull": 150,
  "scenario_base": 142,
  "scenario_bear": 108,
  "scenario_bull_target": 150,
  "scenario_base_target": 142,
  "scenario_bear_target": 108,
  "scenario_prob_bull": 25,
  "scenario_prob_base": 50,
  "scenario_prob_bear": 25,
  "hard_gate_state": "caution",
  "gates_triggered": [],
  "gates_caution": [
    "earnings_event_risk_q2_aug4",
    "accounting_iprd_charge_distortion",
    "keytruda_concentration_patent_cliff",
    "drug_pricing_ira"
  ],
  "do_not_buy_triggers": [],
  "gates_callout": "clear with caution \u2014 earnings within 14d + IPR&D-distorted GAAP (scored clean); Keytruda cliff + IRA as scored headwinds",
  "entry_groups_met": 1,
  "entry_criteria_met": 1,
  "entry_criteria_total": 3,
  "entry_conviction": "Half-Size",
  "exit_groups_live": 0,
  "exit_criteria_met": 0,
  "exit_criteria_total": 3,
  "exit_action": "Hold",
  "thesis_invalidation_floor": "Keytruda biosimilar/competitive (ivonescimab) erosion from 2028 outpaces the pipeline + subcutaneous-Qlex backfill so total revenue is set to decline through 2028-29, and/or a full-year guidance cut or harsher-than-expected IRA outcome \u2014 driver flips to Headwind and the case breaks.",
  "next_update_date": "2026-08-05",
  "next_check_date": "2026-08-05",
  "next_update_basis": "Q2 2026 earnings 2026-08-04 (BMO) +1 trading day; beats the default +14d (2026-08-08)",
  "report_filename": "MRK_Signal_v6_20260725_1641.html"
}

Medium and Long stay BUY (cheap quality + Health-Care tailwind, no amplification as the driver is Neutral). The Short is capped from BUY to HOLD (“buy on confirmation”) purely on entry timing at the 52-wk high — the fundamentals are unchanged. Valuation eased 68→66 (0.77→0.82 anchor ratio) on the price run plus a higher 10-Y. No Do-Not-Buy trigger; the Keytruda 2028 cliff is a scored headwind, not a structural-threat override.

15

Data Sources & Methodology

Audit trail of every data source: fully available (✓), fallback (⚠), or failed (✗), plus provenance-based confidence haircuts.
Data Source Status
✓
get_company_profile / get_yahoo_quote Price $131.07, beta 0.20, mkt cap $324B, ISIN US58933Y1055, 52-wk high $131.74
✓
get_income_statement (6q) Q1-26 GAAP EPS −$1.72 — confirmed ~$9B acquired-IPR&D charge (R&D $12.6B vs ~$3.5B run-rate); scored on CLEAN ~$9.0 forward EPS, not reported
✓
get_financial_ratios Op margin 38.6%, ROE 18.9%, interest cov 17.4x, reported TTM P/E 36.9x (distorted)
✓
get_multi_timeframe_analysis Strongly-bullish confluence; daily breakout on 0.65× volume; at 52-wk high
✓
get_price_target_consensus / summary / grades Consensus $136.33, median $142, high $155; 25 Buy/11 Hold/1 Sell; last-month avg target rising to $146.6
✓
get_analyst_estimates FY27 EPS $9.60, FY28 $10.63 — analysts model flat-to-growing earnings THROUGH the 2028 cliff (pipeline backfill)
✓
get_ratings_snapshot FMP rating B (3/5); D/E score weak (1) but coverage strong
✓
get_related_tickers Peers confirmed: BMY, AZN, PFE, ABBV, GILD, AMGN, JNJ, LLY, VRTX
✓
WebSearch (Keytruda cliff / Qlex / Winrevair / Gardasil / 10-Y) Keytruda $8.0B Q1 (+12%), 2028 US LOE, Qlex $128M; Winrevair $525M (+88%); Gardasil −39% China; ivonescimab + 7 biosimilar filers; 10-Y 4.69% (2026-07-24); Q2 earnings 2026-08-04
⚠
get_earnings_calendar Empty via API — Q2 date (Aug 4 BMO) confirmed by web + merck.com investor events
✗
get_risk_factors Returned empty text bodies; risk narrative sourced from filings-knowledge + web
Impact on scores: Low — all pillar-critical data available; the two gaps (earnings-calendar API, risk-factor bodies) were backfilled from primary/web sources. Earnings-quality trap explicitly handled (clean vs reported).
DISCLAIMER: This is a quantitative framework for educational purposes only. It is not financial advice. Always do your own research and consult a licensed financial advisor before making investment decisions.